| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Arundic acid targets astrocytes, regulating their activation and inhibiting the synthesis of S-100β. S-100β is a protein produced by astrocytes that is involved in neuroinflammation and neuronal damage. By inhibiting S-100β synthesis and regulating astrocyte activation, arundic acid reduces neuroinflammation and protects neurons from damage.
|
|---|---|
| ln Vitro |
In vitro, arundic acid inhibits the synthesis of S-100β and regulates astrocyte activation. These effects have been demonstrated in astrocyte cultures. By modulating astrocyte function, arundic acid reduces the production of neuroinflammatory factors. These in vitro activities confirm its profile as an astrocyte regulator with neuroprotective potential.
|
| ln Vivo |
In vivo, arundic acid delays the expansion of cerebral infarction by inhibiting the synthesis of S-100β and regulating astrocyte activation. It has been investigated for the treatment of ALS. However, specific details of in vivo efficacy studies are not extensively detailed in the available literature. The compound is a research tool for studying neuroinflammation and neurodegeneration.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for arundic acid is not well-defined, as it acts on astrocytes rather than a specific enzyme or receptor. Its effects are typically studied in cellular systems. Its ability to inhibit S-100β synthesis can be assessed in astrocyte cultures by measuring S-100β protein or mRNA levels.
|
| Cell Assay |
In vitro cellular assays for arundic acid assess its effects on astrocyte activation and S-100β synthesis. Astrocytes are treated with arundic acid, and markers of astrocyte activation and S-100β levels are measured. These assays demonstrate the compound's ability to modulate astrocyte function in a relevant cellular context.
|
| Animal Protocol |
In vivo animal studies for arundic acid have been conducted in models of cerebral infarction to assess its neuroprotective effects. It has also been investigated in models of ALS. However, specific details of these studies are not extensively detailed in the available literature. The compound is a research tool for studying neuroinflammation and neurodegeneration.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for arundic acid are not extensively detailed in the available literature. As a small molecule, its pharmacokinetic properties would be important for its in vivo efficacy. However, specific parameters such as oral bioavailability, half-life, and distribution are not provided. The compound is primarily used in research settings.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for arundic acid are not extensively detailed in the available literature. As an astrocyte regulator, its toxicity profile is likely related to its mechanism of action. However, preclinical toxicology studies would be required to assess its safety margin. The compound is intended for research use only.
|
| Additional Infomation |
Alendrolic acid has been investigated for the treatment of amyotrophic lateral sclerosis (ALS).
Drug Indications It has been investigated for the treatment of cerebral ischemia. Mechanism of Action ONO-2506 is a neuroprotective agent because it acts on glial cells. It inhibits the synthesis of calcium-binding protein S100B. ONO-2506 is currently undergoing clinical trials for the treatment of stroke and Alzheimer's disease patients. Arundic acid (ONO-2506) is an astrocyte regulator that delays the expansion of cerebral infarction by inhibiting the synthesis of S-100β and regulating astrocyte activation. It has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS). It is a research compound for studying neuroinflammation and neurodegeneration and is not approved for clinical use. |
| Molecular Formula |
C11H22O2
|
|---|---|
| Molecular Weight |
186.29118
|
| Exact Mass |
186.162
|
| CAS # |
185517-21-9
|
| Related CAS # |
S-(+)-Arundic Acid;807363-10-6
|
| PubChem CID |
208925
|
| Appearance |
Colorless to light yellow liquid（Density：0.908 g/cm3）
|
| Density |
0.908 g/cm3
|
| Boiling Point |
289.3ºC at 760mmHg
|
| Vapour Pressure |
0.000557mmHg at 25°C
|
| Index of Refraction |
1.444
|
| LogP |
3.457
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
13
|
| Complexity |
132
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCC[C@@H](CCC)C(=O)O
|
| InChi Key |
YCYMCMYLORLIJX-SNVBAGLBSA-N
|
| InChi Code |
InChI=1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)/t10-/m1/s1
|
| Chemical Name |
(2R)-2-propyloctanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~150 mg/mL (~805.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 3.75 mg/mL (20.13 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.75 mg/mL (20.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.75 mg/mL (20.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3680 mL | 26.8399 mL | 53.6797 mL | |
| 5 mM | 1.0736 mL | 5.3680 mL | 10.7359 mL | |
| 10 mM | 0.5368 mL | 2.6840 mL | 5.3680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00229177 | Completed | Drug: ONO-2506 Drug: ONO-2506 Drug: ONO-2506 |
Stroke | Ono Pharmaceutical Co. Ltd | 2005-09 | Phase 2 Phase 3 |
| NCT00046761 | Terminated | Drug: ONO-2506 | Cerebrovascular Accident | Ono Pharma USA Inc | 2002-11 | Phase 2 Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
